PMID- 2166971
OWN - NLM
STAT- MEDLINE
DCOM- 19900914
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 58
IP  - 6
DP  - 1990 Jun 15
TI  - Influence of thromboembolism prophylaxis by low molecular weight heparin CY 216 
      (Fraxiparine) on several parameters of haemostasis in patients under dialysis and 
      receiving either unfractionated heparin or CY 216.
PG  - 555-60
AB  - The hemorrhagic risk of an association of the low molecular weight (LMWH), 
      Fraxiparine injected intravenously at the dose of 7.500 AXalCU or of 
      unfractionated heparin (UFH) injected intravenously at the usual dose used during 
      hemodialysis (3.750 +/- 1.280 IU + 1.000 IU after 2 hours of dialysis) to the 
      subcutaneous administration once daily of a thromboembolism preventive dose of 
      Fraxiparine (7.500 AXalCU) was evaluated on the modification of the following 
      hemostasis parameters: thrombin time, activated partial thromboplastin time 
      (APTT), anti Xa activity, in 13 uremic patients on hemodialysis. The association 
      of intravenous and subcutaneous Fraxiparine prevented efficiently the clotting of 
      the extracorporeal circulation without inducing a detectable antithrombinic 
      activity. In contrast, the association of I.V. UFH to subcutaneous Fraxiparine 
      induced a significant increase of the thrombin time and of the APTT, so explained 
      by the activity of UFH. It is concluded that subcutaneous Fraxiparine at the 
      thromboembolism preventive dose can be associated as well to I.V. Fraxiparine as 
      to UFH without increasing the potential hemorrhagic risk. Nevertheless the 
      association of SC and IV Fraxiparine 7.500 AXalC u seems preferable to the 
      association of SC Fraxiparine with UFH.
FAU - Dieval, J
AU  - Dieval J
AD  - Laboratory of Haematology, CHR Amiens, France.
FAU - Moriniere, P
AU  - Moriniere P
FAU - Gross, S
AU  - Gross S
FAU - d'Azemar, P
AU  - d'Azemar P
FAU - Fournier, A
AU  - Fournier A
FAU - Delobel, J
AU  - Delobel J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Clinical Trials as Topic
MH  - Female
MH  - Hemostasis/*drug effects
MH  - Heparin/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Male
MH  - *Renal Dialysis
MH  - Thromboembolism/*prevention & control
EDAT- 1990/06/15 00:00
MHDA- 1990/06/15 00:01
CRDT- 1990/06/15 00:00
PHST- 1990/06/15 00:00 [pubmed]
PHST- 1990/06/15 00:01 [medline]
PHST- 1990/06/15 00:00 [entrez]
AID - 10.1016/0049-3848(90)90301-r [doi]
PST - ppublish
SO  - Thromb Res. 1990 Jun 15;58(6):555-60. doi: 10.1016/0049-3848(90)90301-r.